Clin2
NCT04882839Possibly a fitRecruiting

Therapy with psilocybin for severe OCD symptoms

Obsessive-compulsive Disorder

Part of Mental health clinical trials.

This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
15 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must have a clinician-confirmed OCD diagnosis.
  • Your OCD symptom severity must be high (Y-BOCS score 16 or higher).
  • You must have tried at least one standard OCD treatment (medication and/or therapy) but it did not work well.
  • You must be between 18 and 65 years old and able to attend all sessions and follow-ups.
  • You must stop certain OCD medicines (selective serotonin inhibitors) long enough before starting (five drug “half-lives” plus 2 weeks).
  • You must agree not to start new psychiatric treatments or take psychiatric meds or recreational drugs during the study (unless the study team says otherwise).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06992999Not yet recruiting· Phase 1/Phase 2
Psilocybin for treating OCD

This study tests if a single dose of psilocybin, a psychedelic substance, can safely help people with obsessive-compulsive disorder (OCD) who have not responded well to standard treatments. If you have moderate to severe OCD and have tried at least one recommended treatment without success, you may be able to join.

Tucson, Arizona
NCT07347405Recruiting· Phase 1
Psilocybin Whole Mushroom for OCD Treatment

This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.

Tucson, Arizona
NCT05783817Recruiting· Phase 2
MDMA-assisted therapy for OCD in adults

This trial tests whether MDMA plus cognitive behavioral therapy (CBT) can reduce OCD symptoms in adults who have tried standard OCD treatments before. You may be asked to pause certain medicines and follow specific diet/medication rules around the study session.

Palo Alto, California
NCT04539951Recruiting· Phase 2
Trial for newly treated obsessive-compulsive disorder

This phase 2 study tests an OCD treatment strategy for people who have not yet had OCD medications or recent OCD therapy. It aims to reduce OCD symptoms, especially for those with moderate-to-severe symptom levels.

Shanghai, Shanghai Municipality
NCT07183748Recruiting· Phase 2
Psilocybin microdosing plus therapy for hard-to-treat depression

This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.

Beersheba
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut

Hear when a new Obsessive-Compulsive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.